Right before I left for the winter break, Andrew Gelman and his collaborators lit up social media with a paper claiming that most clinical trials were underpowered. In a paper in NEJM Evidence, they set their sights on the summary statistic everyone loves to hate, the p-value. Gelman referred to this paper as “Bayesians moving from defense to offense.” The coauthors included econ Nobel winner Guido Imbens and prolific epidemiologist Sander Greenland. The paper contained claims like“The probabili...